Company Encyclopedia
View More
name
iRadimed
IRMD.US
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. The company offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers.
1.407 T
IRMD.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking28/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE23.31%A
    • Profit Margin26.31%A
    • Gross Margin77.80%A
  • Growth ScoreB
    • Revenue YoY12.91%B
    • Net Profit YoY13.73%C
    • Total Assets YoY21.72%A
    • Net Assets YoY17.88%A
  • Cash ScoreC
    • Cash Flow Margin380.04%C
    • OCF YoY12.91%B
  • Operating ScoreB
    • Turnover0.77B
  • Debt ScoreA
    • Gearing Ratio14.27%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

    iRadimed CEO Roger Susi sold 5,000 shares of the company's stock at $90.36 per share, totaling $451,800. Post-sale, he owns 2,307,500 shares, a 0.22% decrease in ownership. The sale was disclosed in an SEC filing. iRadimed's stock rose 0.9% to $90.31. The company reported Q3 earnings of $0.47 per share, beating estimates. Analysts forecast a 1.66 EPS for the year. iRadimed announced a quarterly dividend of $0.17 per share. Institutional investors hold 92.34% of the stock. Analysts rate the stock as "Moderate Buy" with a $87.33 target price.

    Market Beat·
    US
    IRMD
    -0.11%
    Market Beat·
    US
    IRMD
    -0.11%

    Chmn Susi Sells 5,000 ($451.8K) Of iRadimed Corp [IRMD]

    Susi Roger E Chairman of the Board of iRadimed Corp [IRMD] filed a Form 4 on November 24, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/24/25TransactionPlanned Sale(1) Shares5,000Price$90.36Value$451,815Ending Holdings: 4,532,950 - Indirect(1) Executed pursuant to a prearranged trading plan (10b5-1).For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

    Reuters·
    US
    IRMD
    -0.11%
    Reuters·
    US
    IRMD
    -0.11%

    IRadimed Director James B. Hawkins Reports Sale of Common Shares

    IRadimed Director James B. Hawkins has reported the sale of common shares of IRadimed Corporation. The announcement was made via EDGAR, the SEC's electronic system, on November 21, 2025. This information is for informational purposes only and not financial advice.

    Reuters·
    US
    IRMD
    -0.11%
    Reuters·
    US
    IRMD
    -0.11%

    Dir Hawkins Files To Sell 3,000 Of iRadimed Corp [IRMD]

    James B. Hawkins, Director of iRadimed Corp, filed a Form 144 with the SEC to sell 3,000 shares of restricted securities on November 20, 2025. The sale will be conducted through Ameriprise Financial LLC. Filing Form 144 is a prerequisite for selling restricted stock, allowing the owner to sell within 90 days of filing.

    Reuters·
    US
    IRMD
    -0.11%
    Reuters·
    US
    IRMD
    -0.11%

    IRadimed CEO Roger E. Susi Reports Disposal of Common Shares

    Roger E. Susi, CEO, President, and Chairman of IRadimed Corporation, reported a disposal of common shares of the company. The full filing is available via EDGAR, the U.S. SEC's system. This news brief was created by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    IRMD
    -0.11%
    Reuters·
    US
    IRMD
    -0.11%
    © 2025 Longbridge｜Disclaimer